STK25 and cancer: This alternative mechanism provides some explanation for the robustness with which loss of STK25 is able to decrease LATS activation, and may also explain why STK25 is frequently focally deleted in a spectrum of human cancers, while MST/MAP4K pathway components are not (Supplementary Table 2).